Chemical rewiring of E3 ubiquitin ligases as a generalizable therapeutic approach

TrickE3 aims to systematically develop monovalent degraders to target undruggable proteins in pancreatic cancer, enhancing drug discovery and expanding the human proteome's targetable space.

Subsidie
€ 1.499.625
2022

Projectdetails

Introduction

Classical drug design relies mostly on the availability of accessible pockets to block specific protein activities. Despite tremendous progress, more than 80% of all human proteins remain beyond the reach of traditional inhibitor-centric approaches. Chemical ablation of protein abundance using bivalent degraders (PROTACs) moves away from an occupancy-driven (inhibition) to an event-driven (binding) pharmacology. However, their design is intrinsically limited to targets that are ligandable via chemical probes. To tackle current unmet clinical problems, we need transformative paradigms.

Potential of Monovalent Degraders

Fortuitous discoveries have illustrated the immense potential of monovalent degraders. These molecules induce the degradation of target proteins by:

  • Molecular gluing to E3 ubiquitin ligases
  • Prompting their destabilization

They have desirable drug-like properties, proven capacity to induce the degradation of proteins otherwise deemed undruggable, and they are already a clinical reality. However, their discovery has been driven by serendipity, thereby hampering their realization as a generalizable drug solution.

Objectives of TrickE3

TrickE3 seeks to establish the foundations for the systematic development of monovalent degraders. To this end, we will:

  1. Develop innovative methodologies to detect and predict drug-induced changes in the interactome/activity of E3s at scale.
  2. Focus on the chemical rewiring of E3s expressed in pancreatic ductal adenocarcinoma (PDAC) due to the imperative need for treatments.
  3. Prospectively identify monovalent degraders (i) of specific vulnerabilities, and (ii) to unlock new PDAC targets.

Impact on Drug Discovery

At the interface of chemical biology and cancer research, TrickE3 will be an instrumental resource to:

  • Broaden drug discovery efforts
  • Probe disease-relevant vulnerabilities
  • Widen the targetable space of the human proteome

We hope to empower other disciplines to chemically explore, without limits, the degradation of relevant targets.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.499.625
Totale projectbegroting€ 1.499.625

Tijdlijn

Startdatum1-3-2022
Einddatum28-2-2027
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)penvoerder

Land(en)

Spain

Vergelijkbare projecten binnen European Research Council

ERC Consolid...

Targeted Protein Degradation as a New Experimental and Therapeutic Approach for Pancreatic Ductal Adenocarcinoma

PROTAC-PDAC aims to develop targeted PROTAC therapies to degrade key oncogenic transcription factors in pancreatic cancer, enhancing treatment efficacy while minimizing toxicity.

€ 1.999.401
ERC Starting...

Deciphering the regulatory logic of the ubiquitin system

This project aims to elucidate the substrate recognition mechanisms of E3 ubiquitin ligases using functional genetic approaches to enhance understanding of the ubiquitin-proteasome system for therapeutic applications.

€ 1.528.843
ERC Consolid...

A general approach for the design of covalent protein proximity inducers

This project aims to expand biochemical perturbations using CoLDR chemistry to create small molecules that activate enzymes, modify PTMs, and control protein interactions for therapeutic applications.

€ 1.998.744
ERC Consolid...

ADPribosylation and Ubiquitination; post-translational interplay

This project aims to investigate the interplay between ubiquitination and ADPribosylation in cellular processes to develop novel therapeutic strategies for diseases like infections and cancer.

€ 1.999.625
ERC Advanced...

Ubiquitin-Proteasome System crosstalk with Metabolism

This project aims to elucidate the regulatory crosstalk between ubiquitination and cellular metabolites using advanced biophysical techniques to enhance understanding of metabolic homeostasis.

€ 2.089.688

Vergelijkbare projecten uit andere regelingen

EIC Accelerator

The ProM platform: New ways to drug the undruggable

PROSION's ProM-platform aims to unlock and target the undruggable 85% of the human proteome, developing new therapies for hard-to-treat diseases like cancer.

€ 2.461.375